Pharmaceutical company Amanta Healthcare has officially filed its draft red herring prospectus (DRHP) with the Securities and Exchange Board of India (SEBI), seeking to raise funds through an initial public offering (IPO). The company is looking to issue up to 1,25,00,000 equity shares with a face value of ₹10 each, all of which will be new shares.
This move is expected to attract investors interested in share market investment, especially in the fast-growing pharmaceutical sector.
Purpose of the IPO
The primary objective of this IPO is to generate funds for capital expenditure, which will be used for civil construction, the purchase of equipment, and setting up a new manufacturing line for SteriPort at Amanta’s facility in Hariyala, Kheda, Gujarat. The funds will also support the establishment of a new Small Volume Parenteral (SVP) manufacturing line at the same location. Additionally, a portion of the raised capital will go towards general corporate purposes.
Lead managers and company profile
Beeline Capital Advisors has been appointed as the book running lead managers for the IPO, while Linktime is serving as the registrar of the issue. Amanta Healthcare, known for its production of sterile liquid products, is a leader in the pharmaceutical industry. The company uses advanced technologies like Aseptic Blow-Fill-Seal (ABFS) and Injection Stretch Blow Moulding (ISBM) to manufacture parenteral solutions, which are vital for patients who cannot take oral medication.
The company’s manufacturing capabilities span large and small-volume parenteral (LVPs and SVPs) across six therapeutic segments, including fluid therapy, ophthalmics, and respiratory care. Amanta also manufactures medical devices with a commitment to high standards. Its facility in Gujarat adheres to global Good Manufacturing Practice (GMP) standards, and its products are exported to 19 countries, with 113 active international product registrations.
Domestic and global reach
Amanta Healthcare has established a significant presence both in India and internationally. Domestically, it markets over 45 generic products through a network of 289 distributors. On a global scale, Amanta partners with other pharmaceutical companies to manufacture products in large volumes. The company is known for its innovative approach to drug delivery systems, and its export operations have contributed to its growing reputation in the global pharmaceutical market.
Industry context
Amanta Healthcare is not alone in its efforts to go public. Other companies, including All Time Plastics, Scoda Tubes, and Dev Accelerator (DevX), have also submitted their draft red herring prospectuses to SEBI, signalling an active period for IPOs in India. This surge in initial public offerings is likely to attract increased interest from investors looking for share market investment opportunities.
With a strong reputation for quality and innovation, Amanta Healthcare’s decision to go public could prove beneficial for the company’s future growth, as well as for potential investors seeking opportunities in the pharmaceutical industry. The company’s focus on capital expenditure and expansion suggests a forward-thinking approach aimed at scaling its operations to meet both domestic and international demand.
For android only